TipRanks
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
US Market
ORIC
Oric Pharmaceuticals
RESEARCH TOOLSreports
Want to see ORIC full AI Analyst Report?

Oric Pharmaceuticals (ORIC) Stock News & Sentiment

525 Followers
Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial
Premium
Company Announcements
Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial
1M ago
ORIC
ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside
Premium
Ratings
ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside
2M ago
ORIC
Oric Pharmaceuticals Expands Inducement Equity Incentive Plan
Premium
Company Announcements
Oric Pharmaceuticals Expands Inducement Equity Incentive Plan
2M ago
8K
ORIC
Oric Shareholders Approve Equity Plan, Governance Measures
Premium
Company Announcements
Oric Shareholders Approve Equity Plan, Governance Measures
4M ago
8K
ORIC
Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained
Premium
Ratings
Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained
4M ago
ORIC
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
Premium
Ratings
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
5M ago
ORIC
ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts
Premium
Ratings
ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts
5M ago
ORIC
More ORIC News >

ORIC News on the Web

ORIC Pharmaceuticals (ORIC) CFO Dominic Piscitelli Sells 13,400 Shares
GuruFocus News
Neutral
ORIC Pharmaceuticals CFO Dominic Piscitelli Sells 600 Shares of ORIC Stock
GuruFocus News
Neutral
ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch
Insider Monkey
Neutral
Oric Pharmaceuticals initiates Himalayas-1 trial
TipRanks News
Bullish
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)
TipRanks News
Bullish
Oric Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
GuruFocus News
Neutral
ORIC Issues 34,800 Stock Options as Inducement Grants: New Hires Poised to Benefit from Multi-Year Vesting
Market Chameleon
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average2.25 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ORIC’s Media Buzz Sentiment?
Currently, no data Available
What is ORIC’s weekly average amount of articles?
In an average week, 2.25 articles about ORIC are published.
    What is ORIC’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    IQVIQVIA Holdings
    GILDGilead Sciences
    ABBVAbbVie
    VRTXVertex Pharmaceuticals
    NVSNovartis
    Showing the stocks with the most bullish news sentiment over the past week